MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Novel Therapy For Prostate Cancer

Back to prostate cancer blog Blogs list Cancer blog  


Subscribe To Prostate Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Novel Therapy For Prostate Cancer

Novel Therapy For Prostate Cancer
A team of University of Iowa Health Care scientists has launched an important clinical trial of a novel therapeutic that may eventually lead to new therapys for men diagnosed with prostate cancer.

The Ad5-TRAIL gene treatment for prostate cancer research trial is a Phase I study designed to test the optimal dosage at which the therapeutic agent can safely be given to patients.

The clinical study is being co-led by Thomas Griffith, Ph.D., (photo, left) an associate professor in the Department of Urology, and Richard Williams, M.D., the Rubin H. Flocks Chair in Urology and professor and head of the UI Department of Urology.

"This is the first use of this type of anti-cancer agent which was developed at the University of Iowa. This new gene treatment may help us successfully manage patients with high-risk prostate cancer," Griffith said. "Ideally, we hope to be able to say at the conclusion of this trial that this novel agent is safe and performs as intended by causing the death of prostate tumor cells with no harm to normal cells. However, being at the initial stages of the trial, it is premature to make any claims until the data is analyzed".

Scientists injected the investigational therapeutic into the malignant prostates of three patients. Then, following a 10-day waiting period, surgeons removed the prostates and are evaluating the results.

"The preliminary results appear promising," Williams (photo, right) said. "The patients have tolerated the therapy without any serious side effects, which we hope will permit us to proceed with the research process".

Investigators plan to enroll up to 12 additional participants in the Phase I segment of the study.

"While the vaccine is not intended to be curative at this stage, the role of the research participants is critically important to what is truly a team effort. Without the involvement of our patients, we could not succeed," said Timothy Ratliff, Ph.D., (photo, left) the Anderson-Hebbeln Professor of Urology, and co-investigator in the study.

Funding for this trial has come from the following sources or agencies:

-- Roy J. Carver Charitable Trust - funds for preparing the clinical-grade virus;.

-- Alliance for Cancer Gene Therapy - preclinical studies;.

-- Holden Comprehensive Cancer Center at the UI - preclinical studies and protocol development;.

-- U.S. Department of Defense - protocol development and clinical trial;.

-- National Institutes of Health - clinical trial and Gelfoam studies.

To create the vaccine, the team used a virus that causes the common cold, but which has been engineered to be non-replicative in humans. The disabled virus, known as an adenovirus, can then be used as a vector, or carrier, of other genes that scientists insert into the virus.

The UI scientists say it will take several years before the therapy could be approved and come into general use, even if it is shown to be effective.

Other UI researchers involved in the study include:

Fadi Joudi, M.D.; Badrinath R. Konety, M.D.; Michael B. Cohen, M.D.; Brian K. Link, M.D.; Barbara Ziegler, program assistant; Tammy Madsen, doctor assistant; and Carlene A. Etscheidt, clinical research coordinator.

Prostate cancer is the third-leading cause of death among men in the United States. African-American males are at a higher risk for the disease than other men.

Holden Comprehensive Cancer Center at the UI is Iowa's only National Cancer Institute (NCI)-designated comprehensive cancer center. NCI-designated comprehensive cancer centers are recognized as the leaders in developing new approaches to cancer prevention and cancer care, conducting leading edge research and educating the public about cancer.


Posted by: Mark    Source




Did you know?
A team of University of Iowa Health Care scientists has launched an important clinical trial of a novel therapeutic that may eventually lead to new therapys for men diagnosed with prostate cancer. The Ad5-TRAIL gene treatment for prostate cancer research trial is a Phase I study designed to test the optimal dosage at which the therapeutic agent can safely be given to patients.

Medicineworld.org: Novel Therapy For Prostate Cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.